Sellas rises on FDA's 'orphan' tag for blood cancer drug

Sellas Life Sciences

21/12/2023 13:32

** Shares of cancer drug developer Sellas Life Sciences
Group  SLS.O  rise ~11.5% to $1.36 premarket
    ** Co says the U.S. Food and Drug Administration has granted
"orphan drug" status to its experimental drug targeting a group
of blood cancers   
    ** The drug, SLS009, is in mid-stage trials in patients with
relapsed or refractory peripheral T-cell lymphomas 
     ** Orphan drug status is given to drugs that treat rare
conditions, and are protected through a series of government
incentives once in market
    ** Up to last close, stock down 48.3% YTD 

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))